Six months into the 117th Congress, the U.S. Senate has recently increased its oversight activities following a slow start. Since April, newly empowered Democratic Members have launched or requested more than 20 inquiries...more
7/6/2021
/ Anti-Competitive ,
Biden Administration ,
Congressional Oversight ,
Coronavirus/COVID-19 ,
Cryptocurrency ,
Cybersecurity ,
Diversity and Inclusion Standards (D&I) ,
Drug Pricing ,
Food and Drug Administration (FDA) ,
Manufacturers ,
Pharmaceutical Industry ,
Popular ,
Relief Measures
On July 11, 2018, the House Energy & Commerce Committee’s Health Subcommittee (the Subcommittee) held a hearing titled, “Opportunities to Improve the 340B Drug Pricing Program.” In addition to hearing from two witness...more
On May 15, 2018, the Senate Committee on Health, Education, Labor and Pensions held a hearing entitled “Examining Oversight Report on the 340B Drug Pricing Program.” Led by Subcommittee Chairman Sen. Lamar Alexander (R-TN),...more
On October 11, 2017, the House Energy & Commerce’s Oversight and Investigations Subcommittee held a hearing entitled “Examining How Covered Entities Utilize the 340B Drug Pricing Program.” This was the Subcommittee’s second...more
On July 18, 2017, the House Energy & Commerce’s Oversight and Investigations Subcommittee held a hearing on “Examining HRSA’s Oversight of the 340B Drug Pricing Program.” The hearing featured a single panel of three federal...more